Abstract:Checkpoint inhibitors have been very successful in various tumors, including melanoma and lung cancer. However, these treatments have failed in other tumors, including pancreatic cancer and glioblastoma. Approaches harnessing the immune response are hindered by multiple factors, including T cell exhaustion. Exhausted T cells are less capable of limiting tumor progression. TOX is particularly important for the transcriptional and epigenetic reprogramming of exhausted T cells, and without TOX, T cells cannot differentiate down the exhaustion pathway. While it is known that NFAT is directly upstream of TOX, our understanding of the pathways that lead to the upregulation of TOX remains incomplete. We hypothesized that tumor necrosis factor (TNF) could be involved in the upregulation of TOX, as TNF has been shown to induce exhaustion and can lead to the translocation of NFAT into the nucleus. While we did not detect an upregulation of the pro-inflammatory TNF receptor type I (TNFR1), we observed significant upregulation of the anti-inflammatory TNF receptor type II (TNFR2) in tumor-infiltrating T cells, but not in lymphoid organs. This local upregulation mimics expression patterns of canonical exhaustion markers and suggests that TNFR2 signaling could be involved in the progression of exhaustion. In support of this hypothesis, TNFR2 expression is correlated other markers of exhaustion, including PD1, TIM3, and TOX. Furthermore, TNFR2 knock out (KO) CD8 T cells have significantly lower expression of TOX, without the concomitant decrease of TIM3. Whereas previous studies have intricately linked TIM3 and TOX expression, these data suggest that TIM3 and TOX are regulated independently. To further evaluate transcriptional regulation of WT and KO T cells, we utilized bulk RNA-sequencing. After performing pathway analyses, we detected a significant reduction of T cell exhaustion, senescence, and immune checkpoint pathways in TNFR2 KO T cells. We identified significant decreases in various exhaustion-related transcription factors and coinhibitory markers. In contrast, we discovered a significant increase in AP1 transcription factors, commonly associated with T cell effector functions. Given this reduced exhaustion profile, we subsequently investigated the influence of TNFR2 on tumor burden. TNFR2 KO mice had significantly less tumor burden following subcutaneous tumor challenges. To make this approach more translatable, we treated mice with a TNFR2 antagonist. While the antagonist alone was not sufficient to improve tumor control, combination with immune checkpoint blockade (anti-PD1) significantly reduced tumor volumes in traditionally resistant models. These data provide evidence for a novel marker of exhaustion that could result in a novel therapeutic strategy. Citation Format: Alexandra Hoyt-Miggelbrink, Jessica Waibl Polania, Aditya Mohan, Luke Wachsmuth, Selena Lorrey, Emily Lerner, Daniel Wilkinson, Andrew Hardigan, Kelly Hotchkiss, Saskia Hemmers, Sarah Cook Quackenbush, Katayoun Ayasoufi, Peter Fecci. TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A056.

Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells

Abstract 7536: CD4+T cell exhaustion in the tumor microenvironment and antitumor immunity

CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site

CD49a Targeting Enhances NK Cell Function and Antitumor Immunity

CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Tumor hypoxia drives suppressor function in exhausted T cells limiting antitumor immunity

Abstract 2635: An epigenetic regulation targeting inhibitory receptors and attenuates CD8 T cell exhaustion in breast cancer

Abstract A056: TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control

Regulatory T cells in tumor immunity

Glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation

Immu-05. Tnfr2 Is A Novel Marker Of Exhaustion And Tnfr2 Blockade Improves Subcutaneous Tumor Control

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing

CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Immunoregulatory T cells in tumor immunity